Skip to Primary Navigation

FDA launches global approval disclosure program to speed medicine access

The GRDP initiative will share regulatory review materials with global health authorities to accelerate access to medicines worldwide.

Article label: Quick Read
Premium article

With the goal of helping health regulators around the world make faster approval decisions on medicines and biologics, the US Food and Drug Administration (FDA) has launched a dedicated program.

The Global Reliance Disclosure Program (GRDP) allows the FDA to provide companies with “minimally redacted approval packages,” including scientific and

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

What’s included:

  • Every new article, plus our 6,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience